Watchlist Sponsored By :
- US Markets Bracing for Selloff on Dubai Debt Worries
- Shoppers Hit Black Friday Sales, Budgets Pared
- US Dollar Falls to 14-Year Low Against the Yen
- Car Insurance Scofflaws Raise Health Reform Doubt
- ING Prices Share Issue at Hefty Discount
- Cheap Robotic Hamsters Are Holiday's Unlikely Craze
- EU Names New Leadership Team to Boost Economy
- Tommy Hilfiger's Estate in Conn. Sells for $20 Million
- UK's Darling to Downgrade 2009 Growth Forecast
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
MOST SHARED
- No Thanksgiving Rest for Retailers in Sales Race
- Banks Play Down Dubai Exposure, Investors Still Wary
- UK's Darling to Downgrade 2009 Growth Forecast
- Attraction of Switzerland to Businesses
- More Asia Executives Resigned to Economy Flights: Survey
- San Miguel Sells $1.36 Billion Stake to Ally
- Oil Falls Below $75 on Dubai Default Worries
powered by digg
Merck, Schering To Develop Combo Pill With Lipitor
Topics:Pharmaceuticals | Medicine
Sectors:Health Care
Companies:Merck & Co Inc | Schering Plough Corp | Pfizer Inc
Text Size 
Merck [MRK
Loading...
()
] and Schering-Plough [SGP
Loading...
()
] said on Monday they were beginning development on a cholesterol-lowering product that would combine their Zetia drug with Pfizer's [PFE
Loading...
()
] Lipitor.
The development program is timed so the combination product could be available when the patent for Lipitor, known generically as atorvastatin, expires in the U.S. and
internationally, the companies said.
Lipitor, the world's largest-selling drug, is expected to face generic competition in the U.S. in 2010 or 2011.
Schering-Plough and Merck already have a joint venture to market Zetia and Vytorin, which combines Zetia with Merck's Zocor.
Click for related content
© 2009 CNBC.com
Print
Email
- What you need to know.
- Social enterprises are becoming a new asset class for the ethically-minded.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
MORE FROM CNBC
TOPIC : Pharmaceuticals
Data is a real-time snapshot *Data is delayed at least 15 minutes